Medical technologies provider Teleflex has finalised its previously announced €760m acquisition of BIOTRONIK’s vascular intervention business.
The deal, which was announced in February 2025, is expected to enhance Teleflex’s global presence in the catheter laboratory market. It will also expand the firm’s range of interventional access products.
The acquired vascular intervention division offers an array of products for both coronary and peripheral interventions. Notable products for coronary interventions include the Pantera Lux Drug-Coated Balloon Catheter and the Orsiro Mission Drug Eluting Stent.
For peripheral interventions, key offerings include the Passeo-18 Lux Peripheral Drug-Coated Balloon Catheter and the Pulsar-18 T3 Self-Expanding 4F Stent.
Teleflex chairman, president, and CEO Liam Kelly said: “We believe the acquisition will allow us to position this advanced coronary portfolio alongside our existing Interventional business and establish our global footprint in the fast-growing peripheral intervention market.
“The acquired business is rooted in robust research and development, clinical expertise, and global manufacturing capabilities, which we believe will further bolster Teleflex’s innovation pipeline, and position the company to participate in the emerging potential for resorbable scaffold technologies.”
With this acquisition, Teleflex plans to invest further in the clinical trial programme for Freesolve, a sirolimus-eluting resorbable metallic scaffold (RMS) technology. Freesolve obtained its CE Mark in February 2024 and has shown promising results in studies such as BIOMAG-I, demonstrating scaffolding resorption after 12 months.
Financial projections suggest that the newly acquired products will generate €177m in revenue during the second half of 2025.
For Q4 2025, revenue is expected to be €91m. From 2026 onwards, Teleflex anticipates annual revenue growth of at least 6% from these products.
The acquisition is projected to boost Teleflex’s adjusted earnings per share by roughly $0.1 in its first year, excluding non-recurring costs.
